Identifying Progression in Multiple Sclerosis: New Perspectives: New Perspectives

Massimo Filippi; Paolo Preziosa; Dawn Langdon; Hans Lassmann; Friedemann Paul; Àlex Rovira; Menno M. Schoonheim; Alessandra Solari; Bruno Stankoff; Maria A. Rocca

doi:https://doi.org/10.1002/ana.25808

Identifying Progression in Multiple Sclerosis: New Perspectives: New Perspectives

Massimo Filippi, Paolo Preziosa, Dawn Langdon, Hans Lassmann, Friedemann Paul, Àlex Rovira, Menno M. Schoonheim, Alessandra Solari, Bruno Stankoff, Maria A. Rocca

Research output: Contribution to journal › Review article › Academic › peer-review

63 Citations (Scopus)

Abstract

The identification of progression in multiple sclerosis is typically retrospective. Given the profound burden of progressive multiple sclerosis, and the recent development of effective treatments for these patients, there is a need to establish measures capable of identifying progressive multiple sclerosis early in the disease course. Starting from recent pathological findings, this review assesses the state of the art of potential measures able to predict progressive multiple sclerosis. Future promising biomarkers that might shed light on mechanisms of progression are also discussed. Finally, expansion of the concept of progressive multiple sclerosis, by including an assessment of cognition, patient-reported outcomes, and comorbidities, is considered. ANN NEUROL 2020;88:438–452.

Original language	English
Pages (from-to)	438-452
Number of pages	15
Journal	Annals of neurology
Volume	88
Issue number	3
Early online date	7 Jun 2020
DOIs	https://doi.org/10.1002/ana.25808
Publication status	Published - 1 Sept 2020

Access to Document

https://doi.org/10.1002/ana.25808

Cite this

@article{4cd151a7443a431bae2691ec95280bfb,

title = "Identifying Progression in Multiple Sclerosis: New Perspectives: New Perspectives",

abstract = "The identification of progression in multiple sclerosis is typically retrospective. Given the profound burden of progressive multiple sclerosis, and the recent development of effective treatments for these patients, there is a need to establish measures capable of identifying progressive multiple sclerosis early in the disease course. Starting from recent pathological findings, this review assesses the state of the art of potential measures able to predict progressive multiple sclerosis. Future promising biomarkers that might shed light on mechanisms of progression are also discussed. Finally, expansion of the concept of progressive multiple sclerosis, by including an assessment of cognition, patient-reported outcomes, and comorbidities, is considered. ANN NEUROL 2020;88:438–452.",

author = "Massimo Filippi and Paolo Preziosa and Dawn Langdon and Hans Lassmann and Friedemann Paul and {\`A}lex Rovira and Schoonheim, {Menno M.} and Alessandra Solari and Bruno Stankoff and Rocca, {Maria A.}",

year = "2020",

month = sep,

day = "1",

doi = "https://doi.org/10.1002/ana.25808",

language = "English",

volume = "88",

pages = "438--452",

journal = "Annals of neurology",

issn = "0364-5134",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - Identifying Progression in Multiple Sclerosis: New Perspectives

T2 - New Perspectives

AU - Filippi, Massimo

AU - Preziosa, Paolo

AU - Langdon, Dawn

AU - Lassmann, Hans

AU - Paul, Friedemann

AU - Rovira, Àlex

AU - Schoonheim, Menno M.

AU - Solari, Alessandra

AU - Stankoff, Bruno

AU - Rocca, Maria A.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - The identification of progression in multiple sclerosis is typically retrospective. Given the profound burden of progressive multiple sclerosis, and the recent development of effective treatments for these patients, there is a need to establish measures capable of identifying progressive multiple sclerosis early in the disease course. Starting from recent pathological findings, this review assesses the state of the art of potential measures able to predict progressive multiple sclerosis. Future promising biomarkers that might shed light on mechanisms of progression are also discussed. Finally, expansion of the concept of progressive multiple sclerosis, by including an assessment of cognition, patient-reported outcomes, and comorbidities, is considered. ANN NEUROL 2020;88:438–452.

AB - The identification of progression in multiple sclerosis is typically retrospective. Given the profound burden of progressive multiple sclerosis, and the recent development of effective treatments for these patients, there is a need to establish measures capable of identifying progressive multiple sclerosis early in the disease course. Starting from recent pathological findings, this review assesses the state of the art of potential measures able to predict progressive multiple sclerosis. Future promising biomarkers that might shed light on mechanisms of progression are also discussed. Finally, expansion of the concept of progressive multiple sclerosis, by including an assessment of cognition, patient-reported outcomes, and comorbidities, is considered. ANN NEUROL 2020;88:438–452.

UR - http://www.scopus.com/inward/record.url?scp=85087566090&partnerID=8YFLogxK

U2 - https://doi.org/10.1002/ana.25808

DO - https://doi.org/10.1002/ana.25808

M3 - Review article

C2 - 32506714

SN - 0364-5134

VL - 88

SP - 438

EP - 452

JO - Annals of neurology

JF - Annals of neurology

IS - 3

ER -

Identifying Progression in Multiple Sclerosis: New Perspectives: New Perspectives

Abstract

Access to Document

Other files and links

Cite this